Susumu Iiizumi
Kihara Institute for Biological Research
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Susumu Iiizumi.
Journal of Biological Chemistry | 2008
Eriko Toyoda; Shigehide Kagaya; Ian G. Cowell; Aya Kurosawa; Keiichi Kamoshita; Kiyohiro Nishikawa; Susumu Iiizumi; Hideki Koyama; Caroline A. Austin; Noritaka Adachi
Topoisomerase II (Top2) is a ubiquitous nuclear enzyme that relieves torsional stress in chromosomal DNA during various cellular processes. Agents that target Top2, involving etoposide, doxorubicin, and mitoxantrone, are among the most effective anticancer drugs used in the clinic. Mammalian cells possess two genetically distinct Top2 isoforms, both of which are the target of these agents. Top2α is essential for cell proliferation and is highly expressed in vigorously growing cells, whereas Top2β is nonessential for growth and has recently been implicated in treatment-associated secondary malignancies, highlighting the validity of a Top2α-specific drug for future cancer treatment; however, no such agent has been hitherto reported. Here we show that NK314, a novel synthetic benzo[c]phenanthridine alkaloid, targets Top2α and not Top2β in vivo. Unlike other Top2 inhibitors, NK314 induces Top2-DNA complexes and double-strand breaks (DSBs) in an α isoform-specific manner. Heterozygous disruption of the human TOP2α gene confers increased NK314 resistance, whereas TOP2β homozygous knock-out cells display increased NK314 sensitivity, indicating that the α isoform is the cellular target. We further show that the absence of Top2β does not alleviate NK314 hypersensitivity of cells deficient in non-homologous end-joining, a critical pathway for repairing Top2-mediated DSBs. Our results indicate that NK314 acts as a Top2α-specific poison in mammalian cells, with excellent potential as an efficacious and safe chemotherapeutic agent. We also suggest that a series of human knock-out cell lines are useful in assessing DNA damage and repair induced by potential topoisomerase-targeting agents.
BioTechniques | 2006
Susumu Iiizumi; Yuji Nomura; Sairei So; Koichi Uegaki; Kayoko Aoki; Kei-ichi Shibahara; Noritaka Adachi; Hideki Koyama
Targeted gene disruption is a powerful tool for studying gene function in cells and animals. In addition, this technology includes a potential to correct disease-causing mutations. However, constructing targeting vectors is a laborious step in the gene-targeting strategy, even apart from the low efficiency of homologous recombination in mammals. Here, we introduce a quick and simplified method to construct targeting vectors. This method is based on the commercially available MultiSite Gateway technology. The sole critical step is to design primers to PCR amplify genomic fragments for homologous DNA arms, after which neither ligation reaction nor extensive restriction mapping is necessary at all. The method therefore is readily applicable to embryonic stem (ES) cell studies as well as all organisms whose genome has been sequenced. Recently, we and others have shown that the human pre-B cell line Nalm-6 allows for high-efficiency gene targeting. The combination of the simplified vector construction system and the high-efficiency gene targeting in the Nalm-6 cell line has enabled rapid disruption of virtually any locus of the human genome within one month, and homozygous knockout clones lacking a human gene of interest can be created within 2-3 months. Thus, our system greatly facilitates reverse genetic studies of mammalian--particularly human--genes.
Nucleic Acids Research | 2008
Susumu Iiizumi; Aya Kurosawa; Sairei So; Yasuyuki Ishii; Yuichi Chikaraishi; Ayako Ishii; Hideki Koyama; Noritaka Adachi
In higher animal cells, the principal limitation of gene-targeting technology is the extremely low efficiency of targeted integration, which occurs three to four orders of magnitude less frequently than random integration. Assuming that random integration mechanistically involves non-homologous end-joining (NHEJ), inactivation of this pathway should reduce random integration and may enhance gene targeting. To test this possibility, we examined the frequencies of random and targeted integration in NHEJ-deficient chicken DT40 and human Nalm-6 cell lines. As expected, loss of NHEJ resulted in drastically reduced random integration in DT40 cells. Unexpectedly, however, this was not the case for Nalm-6 cells, indicating that NHEJ is not the sole mechanism of random integration. Nevertheless, we present evidence that NHEJ inactivation can lead to enhanced gene targeting through a reduction of random integration and/or an increase in targeted integration by homologous recombination. Most intriguingly, our results show that, in the absence of functional NHEJ, random integration of targeting vectors occurs more frequently than non-targeting vectors (harboring no or little homology to the host genome), implying that suppression of NHEJ-independent random integration events is needed to greatly enhance gene targeting in animal cells.
International Journal of Hematology | 2012
Rikiya Sato; Susumu Iiizumi; E. Kim; Fumiko Honda; Sang-Kyou Lee; Noritaka Adachi; Hideki Koyama; Shuki Mizutani; Tomohiro Morio
Wiskott–Aldrich syndrome (WAS) is an X-linked immunodeficiency disease affecting cell morphology and signal transduction in hematopoietic cells. The function of Wiskott–Aldrich syndrome protein (WASp) and its partners in protein interaction have been studied intensively in mice; however, detailed biochemical characterization of its signal transduction and assessment of its functional consequence in human WASp-deficient lymphocytes remain difficult. In this study, we generated Nalm-6 cells in which the WAS protein gene (WASP) was disrupted by homologous recombination-based gene targeting and a cell-permeable form of recombinant WASp for functional study. The WASP−/− cells showed impaired adhesive capacity and polarization to plate-bound anti-CD47 mAb, anti-CD9 mAb, or to fibronectin. The defective morphological changes were accompanied by impaired intracellular signaling. In addition, the WASp-deficient cells displayed augmented apoptosis induced by CD24 cross-linking. A recombinant fusion protein composed of Hph-1 cell-permeable peptide and WASp prepared in Escherichia coli. Hph-1-WASp was efficiently transduced and expressed in WASP−/− Nalm-6 cells in a dose-dependent manner. The wild-type WASp, but not the mutant restored adhesion capacity, spreading morphology, and cytoskeletal reorganization. Additionally, the recombinant protein was successfully transduced into normal lymphocytes. These findings suggest that gene-disrupted model cell lines and cell-permeable recombinant proteins may serve as important tools for the detailed analysis of intracellular molecules involved in PID.
Journal of Biological Chemistry | 2003
Noritaka Adachi; Hiromi Suzuki; Susumu Iiizumi; Hideki Koyama
DNA and Cell Biology | 2006
Noritaka Adachi; Sairei So; Susumu Iiizumi; Yuji Nomura; Kyoko Murai; Chie Yamakawa; Kiyoshi Miyagawa; Hideki Koyama
Biochemical and Biophysical Research Communications | 2004
Noritaka Adachi; Susumu Iiizumi; Sairei So; Hideki Koyama
DNA and Cell Biology | 2008
Aya Kurosawa; Hideki Koyama; Shinichi Takayama; Kensuke Miki; Dai Ayusawa; Michihiko Fujii; Susumu Iiizumi; Noritaka Adachi
DNA Repair | 2006
Koichi Uegaki; Noritaka Adachi; Sairei So; Susumu Iiizumi; Hideki Koyama
Journal of Biotechnology | 2009
Tatsuya Ono; Hitoshi Nishijima; Noritaka Adachi; Susumu Iiizumi; Akane Morohoshi; Hideki Koyama; Keiichi Shibahara